Dr. Kooienga is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
130 Rampart Way
Suite 300b
Denver, CO 80230Phone+1 303-364-4775
Education & Training
University of ColoradoFellowship, Nephrology, 2004 - 2007- University of ColoradoResidency, Internal Medicine, 2000 - 2004
Wayne State University School of MedicineClass of 2000
Certifications & Licensure
CO State Medical License 2003 - 2025
KS State Medical License 2012 - 2023- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Nephrology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012-2013
Publications & Presentations
PubMed
- 33 citationsHow long is the warranty period for nil or low coronary artery calcium in patients new to hemodialysisAntonio Bellasi, Laura Kooienga, Geoffrey A. Block, Emir Veledar, David Spiegel
Journal of Nephrology. 2009-03-01 - 562 citationsMortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients.Geoffrey A. Block, Paolo Raggi, Antonio Bellasi, Laura Kooienga, David Spiegel
Kidney International. 2007-03-01 - 42 citationsEfficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.Brad H Rovin, Jonathan Barratt, Hiddo J L Heerspink, Charles E Alpers, Stewart Bieler
Lancet. 2023-12-02
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
